Supporting the concept that hematologic indices reflect inflammatory burden, baseline low MLR (monocyte‐to‐lymphocyte ratio, a hematologic index correlating with SII) forecasts 52‐week PASI100 response to IL‐17A/F blockade in psoriasis [37]. This evidence concerns the gene IL17A and psoriasis.